Research Analysts’ Recent Ratings Changes for Clarivate (CLVT)

Clarivate (NYSE: CLVT) recently received a number of ratings updates from brokerages and research firms:

• 8/1/2026 – Clarivate was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/30/2026 – Clarivate had its price target lowered by Barclays PLC from $2.50 to $2.00. They now have an “underweight” rating on the stock.
• 7/30/2026 – Clarivate had its price target lowered by Citigroup Inc. from $2.80 to $2.50. They now have a “neutral” rating on the stock.
• 7/30/2026 – Clarivate had its price target lowered by The Goldman Sachs Group, Inc. from $2.90 to $2.60. They now have a “neutral” rating on the stock.
• 7/30/2026 – Clarivate had its price target lowered by Stifel Nicolaus from $6.00 to $5.00. They now have a “buy” rating on the stock.
• 7/7/2026 – Clarivate had its price target raised by Barclays PLC from $2.40 to $2.50. They now have an “underweight” rating on the stock.
• 6/24/2026 – Clarivate had its “sell (e+)” rating reaffirmed by Weiss Ratings.

Insiders Place Their Bets

In related news, Director Andrew Miles Snyder sold 2,489,618 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $1.94, for a total transaction of $4,829,858.92. Following the completion of the sale, the director owned 3,856,597 shares of the company’s stock, valued at $7,481,798.18. This represents a 39.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Kenneth L. Cornick acquired 650,000 shares of Clarivate stock in a transaction on Thursday, August 6th. The shares were purchased at an average price of $1.86 per share, for a total transaction of $1,209,000.00. Following the completion of the purchase, the director directly owned 1,750,000 shares of the company’s stock, valued at approximately $3,255,000. This represents a 59.09% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 22.88% of the stock is currently owned by company insiders.

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.